-August 31, 2023-The French channel France 3 dedicated a report on BOYDSense, the Alpha MOS subsidiary specialized in medical applications, that works on a pain-free device to monitor glucose levels with exhaled breath. The journalists also interviewed Pr. Pierre Gourdy, diabetes specialist within Toulouse CHU, who managed the a clinical study conducted on 130 patients with Type-2 […]

-July 17, 2023-The Toulouse-based company frees diabetics from finger pricks: BOYDSense, an Alpha MOS company, is finalizing the development of an electronic breath glucose meter that could well change the lives of people with diabetes. The full article is available online, in French, for subscribers only.

-May 12, 2022-BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN : FR0013421286 ALNEO) , announces that they have been selected for the final phase of the DCB Innovation Challenge 2022, in the category “diabetes devices”. In the last few years, diabetes technology has made enormous progress in improving the lives of people with diabetes. However, there […]

-February 3, 2022-BOYDSense SAS, a subsidiary of Alpha MOS (EuroNext: ALNEO), is developing a miniaturized breath analysis platform to monitor chronic diseases, with a first application in diabetes. Today, BOYDSense is announcing the appointment of Ben Delhey as CEO of the company. Ben Delhey has more than 20 years of senior management experience in the healthcare industry […]

-December 16, 2021-Alpha MOS announces that its MedTech subsidiary BOYDSense has been selected by the European Innovation Council (EIC) Accelerator of the Horizon Europe funding program. This award recognizes the excellence of its work in medical innovation dedicated to the monitoring of chronic diseases. This €2.5M grant will accelerate the development of a miniaturized breath analyzer for […]

-June 15, 2021-BOYDSense SAS, a subsidiary of Alpha MOS (EuroNext: ALM), developed a miniaturized respiratory analysis platform to monitor chronic diseases, with a first application in diabetes monitoring. Today, BOYDSense is announcing the arrival mid-June of Ben Delhey as Supervisory Board independent member. Ben Delhey has more than 15 years of senior management experience in the Healthcare […]

-June 15, 2021-The University Hospital (CHU) of Toulouse and BOYDSense entered into an agreement to perform a clinical study to enhance and validate on a cohort of 100 people with type 2 diabetes the accuracy of the non-invasive glucose monitoring device developed by Alpha MOS’ subsidiary BOYDSense.This is the second clinical study ordered by BOYDSense. The first […]

-October 8, 2020-Toulouse (France) and Vienna (Austria), October 2nd, 2020. Sweet Ventures entered into an investment agreement to support the development of Alpha MOS’ subsidiary BOYDSense into a leading provider of non-invasive breath analysis-based solutions to monitor diabetes and other chronic conditions. Sweet Ventures is an investment group formed by the founders and early team members of […]

-October 28, 2019-Company’s non-invasive breath analysis technology recognized for its innovation and potential to disrupt glucose monitoring industry. San Bruno, Calif. –  October 29, 2019 – Medical technology company BOYDSense, Inc. has returned from the RESI (Redefining Early Stage Investments) conference in Boston with a second-place finish in the RESI Innovation Challenge and myriad accolades from both investors and […]